Sinopharm Hyundai announced that the company received “Drug Registration Certificates” for dagliflozin tablets and acarbose tablets approved and issued by the State Drug Administration, and treated it as if they had passed the consistency evaluation. Dapagliflozin tablets are suitable for adults with type 2 diabetes, etc., with sales of 9.831 billion yuan in 2025, and the company invested about 9.869 million yuan in R&D; acarbose tablets for type 2 diabetes, etc., had sales of 2,128 billion yuan in 2025, with a cumulative R&D investment of about 17.558 million yuan. This certification expands the product range and enhances competitiveness, but there is no significant impact on current results, and there is uncertainty about drug sales.

Sinopharm Hyundai announced that the company received “Drug Registration Certificates” for dagliflozin tablets and acarbose tablets approved and issued by the State Drug Administration, and treated it as if they had passed the consistency evaluation. Dapagliflozin tablets are suitable for adults with type 2 diabetes, etc., with sales of 9.831 billion yuan in 2025, and the company invested about 9.869 million yuan in R&D; acarbose tablets for type 2 diabetes, etc., had sales of 2,128 billion yuan in 2025, with a cumulative R&D investment of about 17.558 million yuan. This certification expands the product range and enhances competitiveness, but there is no significant impact on current results, and there is uncertainty about drug sales.